These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38937437)

  • 21. Analysis of the molecular mechanism of SARS-CoV-2 antibodies.
    Jin D; Wei J; Sun J
    Biochem Biophys Res Commun; 2021 Aug; 566():45-52. PubMed ID: 34116356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain.
    Liu B; Liu H; Han P; Wang X; Wang C; Yan X; Lei W; Xu K; Zhou J; Qi J; Fan R; Wu G; Tian WX; Gao GF; Wang Q
    Signal Transduct Target Ther; 2024 May; 9(1):131. PubMed ID: 38740785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
    Lim SA; Gramespacher JA; Pance K; Rettko NJ; Solomon P; Jin J; Lui I; Elledge SK; Liu J; Bracken CJ; Simmons G; Zhou XX; Leung KK; Wells JA
    MAbs; 2021; 13(1):1893426. PubMed ID: 33666135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.
    Mast FD; Fridy PC; Ketaren NE; Wang J; Jacobs EY; Olivier JP; Sanyal T; Molloy KR; Schmidt F; Rutkowska M; Weisblum Y; Rich LM; Vanderwall ER; Dambrauskas N; Vigdorovich V; Keegan S; Jiler JB; Stein ME; Olinares PDB; Herlands L; Hatziioannou T; Sather DN; Debley JS; Fenyö D; Sali A; Bieniasz PD; Aitchison JD; Chait BT; Rout MP
    Elife; 2021 Dec; 10():. PubMed ID: 34874007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
    Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
    Front Immunol; 2021; 12():750386. PubMed ID: 34764961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
    Schoof M; Faust B; Saunders RA; Sangwan S; Rezelj V; Hoppe N; Boone M; Billesbølle CB; Puchades C; Azumaya CM; Kratochvil HT; Zimanyi M; Deshpande I; Liang J; Dickinson S; Nguyen HC; Chio CM; Merz GE; Thompson MC; Diwanji D; Schaefer K; Anand AA; Dobzinski N; Zha BS; Simoneau CR; Leon K; White KM; Chio US; Gupta M; Jin M; Li F; Liu Y; Zhang K; Bulkley D; Sun M; Smith AM; Rizo AN; Moss F; Brilot AF; Pourmal S; Trenker R; Pospiech T; Gupta S; Barsi-Rhyne B; Belyy V; Barile-Hill AW; Nock S; Liu Y; Krogan NJ; Ralston CY; Swaney DL; García-Sastre A; Ott M; Vignuzzi M; ; Walter P; Manglik A
    Science; 2020 Dec; 370(6523):1473-1479. PubMed ID: 33154106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
    Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
    Cornish K; Huo J; Jones L; Sharma P; Thrush JW; Abdelkarim S; Kipar A; Ramadurai S; Weckener M; Mikolajek H; Liu S; Buckle I; Bentley E; Kirby A; Han X; Laidlaw SM; Hill M; Eyssen L; Norman C; Le Bas A; Clarke J; James W; Stewart JP; Carroll M; Naismith JH; Owens RJ
    Open Biol; 2024 Jun; 14(6):230252. PubMed ID: 38835241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
    Chen X; Gentili M; Hacohen N; Regev A
    Nat Commun; 2021 Sep; 12(1):5506. PubMed ID: 34535642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD.
    Liu X; Wang Y; Sun L; Xiao G; Hou N; Chen J; Wang W; Xu X; Gu Y
    Antiviral Res; 2024 Jun; 226():105898. PubMed ID: 38692413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
    Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
    Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus.
    Ketaren NE; Mast FD; Fridy PC; Olivier JP; Sanyal T; Sali A; Chait BT; Rout MP; Aitchison JD
    Elife; 2024 May; 12():. PubMed ID: 38712823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.